QIAGEN Market Cap 2010-2022 | QGEN

QIAGEN market cap history and chart from 2010 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. QIAGEN market cap as of December 05, 2022 is $11.17B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.167B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $171.581B 10.47
GSK (GSK) United Kingdom $71.504B 8.96
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.492B 0.00
Myovant Sciences (MYOV) United Kingdom $2.595B 0.00
Arcus Biosciences (RCUS) United States $2.459B 36.91
Biohaven (BHVN) United States $1.112B 0.00
Emergent Biosolutions (EBS) United States $0.588B 4.62
Zymeworks (ZYME) Canada $0.480B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.270B 0.00
Enzo Biochem (ENZ) United States $0.092B 0.00
SQZ Biotechnologies (SQZ) United States $0.042B 0.00
Gelesis Holdings (GLS) United States $0.032B 0.00
Ambrx Biopharma (AMAM) United States $0.020B 0.00